Evidence map›Paper›PMID 25566206›Full record

ArticleFrontiers in microbiology2014

Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection.

Susanne H Hodgson, Elizabeth Juma, Amina Salim, Charles Magiri, Domtila Kimani, Daniel Njenga, Alfred Muia, Andrew O Cole, Caroline Ogwang, Ken Awuondo and 25 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 1 pooled it
10.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 1 synthesis or guideline pooled it, 120 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Increase of Dose Associated With Decrease in Protection Against Controlled Human Malaria Infection by PfSPZ Vaccine in Tanzanian Adults.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Trial
  4. Safety and Differential Antibody and T-Cell Responses to theThe American journal of tropical medicine and hygiene · 2019
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Review
  15. Review
  16. Controlled Human Malaria Infection Studies in Africa-Past, Present, and Future.Current topics in microbiology and immunology · 2024
    Review
  17. Article
  18. Article
  19. Review
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors at 6 institutions in 3 countries.

Susanne H HodgsonThe Jenner Institute, University of Oxford Oxford, UK.
Elizabeth JumaCentre for Clinical Research, Kenya Medical Research Institute Nairobi, Kenya ; Centre for Research in Therapeutic Sciences, Strathmore University Nairobi, Kenya.
Amina SalimCentre for Geographical Medical Research (Coast), Kenya Medical Research Institute - Wellcome Trust Kilifi, Kenya.
Charles MagiriCentre for Clinical Research, Kenya Medical Research Institute Nairobi, Kenya.
Domtila KimaniCentre for Geographical Medical Research (Coast), Kenya Medical Research Institute - Wellcome Trust Kilifi, Kenya.
Daniel NjengaCentre for Clinical Research, Kenya Medical Research Institute Nairobi, Kenya.
Alfred MuiaCentre for Clinical Research, Kenya Medical Research Institute Nairobi, Kenya.
Andrew O ColeCentre for Clinical Research, Kenya Medical Research Institute Nairobi, Kenya ; Centre for Research in Therapeutic Sciences, Strathmore University Nairobi, Kenya.
Caroline OgwangCentre for Geographical Medical Research (Coast), Kenya Medical Research Institute - Wellcome Trust Kilifi, Kenya.
Ken AwuondoCentre for Geographical Medical Research (Coast), Kenya Medical Research Institute - Wellcome Trust Kilifi, Kenya.
Brett LoweCentre for Geographical Medical Research (Coast), Kenya Medical Research Institute - Wellcome Trust Kilifi, Kenya.
Marianne MuneneCentre for Geographical Medical Research (Coast), Kenya Medical Research Institute - Wellcome Trust Kilifi, Kenya.
Peter F BillingsleySanaria Inc. Rockville, MD, USA.
Eric R JamesSanaria Inc. Rockville, MD, USA.
Anusha GunasekeraSanaria Inc. Rockville, MD, USA.
B Kim L SimSanaria Inc. Rockville, MD, USA.
Patricia NjugunaCentre for Geographical Medical Research (Coast), Kenya Medical Research Institute - Wellcome Trust Kilifi, Kenya.
Thomas W RamplingThe Jenner Institute, University of Oxford Oxford, UK.
Adam RichmanSanaria Inc. Rockville, MD, USA.
Yonas AbebeSanaria Inc. Rockville, MD, USA.
Gathoni KamuyuCentre for Geographical Medical Research (Coast), Kenya Medical Research Institute - Wellcome Trust Kilifi, Kenya.
Michelle MuthuiCentre for Geographical Medical Research (Coast), Kenya Medical Research Institute - Wellcome Trust Kilifi, Kenya.
Sean C EliasThe Jenner Institute, University of Oxford Oxford, UK.
Sassy MolyneuxCentre for Geographical Medical Research (Coast), Kenya Medical Research Institute - Wellcome Trust Kilifi, Kenya.
Stephen GerryCentre for Statistics in Medicine, University of Oxford Oxford, UK.
Alex MachariaCentre for Geographical Medical Research (Coast), Kenya Medical Research Institute - Wellcome Trust Kilifi, Kenya.
Thomas N WilliamsCentre for Geographical Medical Research (Coast), Kenya Medical Research Institute - Wellcome Trust Kilifi, Kenya ; Department of Medicine, Imperial College London London, UK.
Peter C BullCentre for Geographical Medical Research (Coast), Kenya Medical Research Institute - Wellcome Trust Kilifi, Kenya.
Adrian V S HillThe Jenner Institute, University of Oxford Oxford, UK.
Faith H OsierCentre for Geographical Medical Research (Coast), Kenya Medical Research Institute - Wellcome Trust Kilifi, Kenya.
Simon J DraperThe Jenner Institute, University of Oxford Oxford, UK.
Philip BejonCentre for Geographical Medical Research (Coast), Kenya Medical Research Institute - Wellcome Trust Kilifi, Kenya.
Stephen L HoffmanSanaria Inc. Rockville, MD, USA.
Bernhards OgutuCentre for Clinical Research, Kenya Medical Research Institute Nairobi, Kenya ; Centre for Research in Therapeutic Sciences, Strathmore University Nairobi, Kenya.
Kevin MarshCentre for Geographical Medical Research (Coast), Kenya Medical Research Institute - Wellcome Trust Kilifi, Kenya.
Kenya Medical Research Institute · KESanaria · USJenner Institute · GBUniversity of Oxford · GBImperial College London · GBStrathmore University · KE

Funding

Universal Attenuated Sporozoite Vaccine and Challenge SystemR44AI058375 · NIAID · SANARIA, INC. · PI HOFFMAN, STEPHEN LEV · 2006 to 2018
$9.9M
Medical Research Council G1000527NIAID NIH HHS R44 AI058375Wellcome Trust 091758Wellcome Trust 092654
6 · The paper itself

Abstract

backgroundControlled human malaria infection (CHMI) studies are a vital tool to accelerate vaccine and drug development. As CHMI trials are performed in a controlled environment, they allow unprecedented, detailed evaluation of parasite growth dynamics (PGD) and immunological responses. However, CHMI studies have not been routinely performed in malaria-endemic countries or used to investigate mechanisms of naturally-acquired immunity (NAI) to Plasmodium falciparum.

methodsWe conducted an open-label, randomized CHMI pilot-study using aseptic, cryopreserved P. falciparum sporozoites (PfSPZ Challenge) to evaluate safety, infectivity and PGD in Kenyan adults with low to moderate prior exposure to P. falciparum (Pan African Clinical Trial Registry: PACTR20121100033272).

resultsAll participants developed blood-stage infection confirmed by quantitative polymerase chain reaction (qPCR). However one volunteer (110) remained asymptomatic and blood-film negative until day 21 post-injection of PfSPZ Challenge. This volunteer had a reduced parasite multiplication rate (PMR) (1.3) in comparison to the other 27 volunteers (median 11.1). A significant correlation was seen between PMR and screening anti-schizont Enzyme Linked Immunosorbent Assays (ELISA) OD (p = 0.044, R = -0.384) but not when volunteer 110 was excluded from the analysis (p = 0.112, R = -0.313).

conclusionsPfSPZ Challenge is safe and infectious in malaria-endemic populations and could be used to assess the efficacy of malaria vaccines and drugs in African populations. Whilst our findings are limited by sample size, our pilot study has demonstrated for the first time that NAI may impact on PMR post-CHMI in a detectable fashion, an important finding that should be evaluated in further CHMI studies.

Indexed as

challengeCHMIfalciparumimmunitymalaria

Identifiers

PMID25566206
PMCPMC4264479
OpenAlexW2038223781

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.